Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy.

Tytuł:
Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy.
Autorzy:
Zhang F; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Huang J; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China; Pharmacology and Toxicology Division, Shanghai Institute of Food and Drug Control, Shanghai, China.
Liu W; Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wang CR; Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Liu YF; Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Tu DZ; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Liang XM; Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Yang L; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhang WD; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Chen HZ; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ge GB; Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Electronic address: .
Źródło:
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2021 Mar; Vol. 149, pp. 111998. Date of Electronic Publication: 2021 Jan 19.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: Exeter : Elsevier Science Ltd
Original Publication: Oxford ; New York : Pergamon Press, c1982-
MeSH Terms:
Herb-Drug Interactions*
COVID-19 Drug Treatment*
Cytochrome P-450 CYP3A/*metabolism
Drugs, Chinese Herbal/*pharmacology
Animals ; Area Under Curve ; China ; Drugs, Chinese Herbal/therapeutic use ; Lopinavir/pharmacokinetics ; Male ; Microsomes, Liver ; NADP/metabolism ; Phytotherapy ; Rats, Sprague-Dawley ; SARS-CoV-2 ; Rats
References:
Curr Opin Lipidol. 2002 Jun;13(3):273-83. (PMID: 12045397)
Chin J Nat Med. 2019 Nov;17(11):801-802. (PMID: 31831127)
Eur J Pharm Sci. 2011 Jun 14;43(3):160-73. (PMID: 21540107)
Eur J Med Chem. 2021 Jan 1;209:112856. (PMID: 33007602)
Chem Biol Interact. 2015 Oct 5;240:346-52. (PMID: 26335194)
Arch Gerontol Geriatr. 2020 Jul - Aug;89:104058. (PMID: 32339960)
Pharmacol Res. 2020 Nov;161:105290. (PMID: 33181320)
Drug Metab Dispos. 2002 Jun;30(6):709-15. (PMID: 12019199)
Acta Pharm Sin B. 2020 Jul;10(7):1149-1162. (PMID: 32834946)
Br J Clin Pharmacol. 2010 Feb;69(2):193-9. (PMID: 20233183)
J Biol Chem. 2010 Oct 22;285(43):32720-32733. (PMID: 20732876)
Medicine (Baltimore). 2020 Sep 4;99(36):e22040. (PMID: 32899063)
Chem Commun (Camb). 2016 Feb 21;52(15):3183-6. (PMID: 26809686)
Int J Biol Macromol. 2018 Dec;120(Pt B):1944-1954. (PMID: 30268757)
Chem Biol Interact. 2019 Aug 1;308:339-349. (PMID: 31170387)
Pharm Res. 2004 Sep;21(9):1622-30. (PMID: 15497688)
Drug Metab Dispos. 2020 May;48(5):345-352. (PMID: 32086296)
Food Chem Toxicol. 2020 Sep;143:111514. (PMID: 32590074)
Coord Chem Rev. 2021 Jan 15;427:213601. (PMID: 33024340)
Chin Med. 2020 Apr 15;15:34. (PMID: 32308732)
Phytomedicine. 2021 May;85:153315. (PMID: 32978039)
J Pharm Pharmacol. 2020 Jul;72(7):979-989. (PMID: 32285478)
Biol Reprod. 2020 Aug 4;103(2):427-436. (PMID: 32285106)
Biomed Pharmacother. 2020 Sep;129:110281. (PMID: 32554251)
Nature. 2016 Mar 17;531(7594):381-5. (PMID: 26934220)
Biochem Pharmacol. 1997 Sep 1;54(5):605-11. (PMID: 9337077)
Pharmacol Ther. 2021 Feb;218:107670. (PMID: 32891711)
Expert Rev Anti Infect Ther. 2020 Jul;18(7):617-624. (PMID: 32362193)
Biomed Pharmacother. 2020 Sep;129:110500. (PMID: 32768975)
Clin Pharmacol Ther. 2021 Jan;109(1):253-262. (PMID: 32691891)
ACS Appl Mater Interfaces. 2015 Dec 30;7(51):28474-81. (PMID: 26641926)
Biol Pharm Bull. 2011;34(1):66-70. (PMID: 21212519)
Medicine (Baltimore). 2020 May 29;99(22):e20489. (PMID: 32481460)
J Med Internet Res. 2020 Jun 12;22(6):e19934. (PMID: 32496205)
Medicine (Baltimore). 2020 Aug 14;99(33):e21284. (PMID: 32871986)
Acta Pharmacol Sin. 2013 Oct;34(10):1349-58. (PMID: 23892274)
J Pharm Pharmacol. 2017 Jul;69(7):823-833. (PMID: 28317117)
Phytomedicine. 2020 Oct;77:153287. (PMID: 32739573)
Int J Biol Macromol. 2019 Sep 15;137:261-269. (PMID: 31260759)
Pharmacol Res. 2020 Jul;157:104820. (PMID: 32360484)
J Adv Res. 2017 Nov 24;11:33-41. (PMID: 30034874)
Contributed Indexing:
Keywords: CYP3A substrate-drugs; Cytochrome P450 enzymes (CYPs/P450s); Herb-drug interactions (HDIs); Qingfei Paidu decoction (QPD)
Substance Nomenclature:
0 (Drugs, Chinese Herbal)
0 (fructus aurantii immaturus)
0 (qingfei paidu decoction)
2494G1JF75 (Lopinavir)
53-59-8 (NADP)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)
Entry Date(s):
Date Created: 20210121 Date Completed: 20210305 Latest Revision: 20240226
Update Code:
20240226
PubMed Central ID:
PMC7816587
DOI:
10.1016/j.fct.2021.111998
PMID:
33476691
Czasopismo naukowe
Corona Virus Disease 2019 (COVID-19) has spread all over the world and brings significantly negative effects on human health. To fight against COVID-19 in a more efficient way, drug-drug or drug-herb combinations are frequently used in clinical settings. The concomitant use of multiple medications may trigger clinically relevant drug/herb-drug interactions. This study aims to assay the inhibitory potentials of Qingfei Paidu decoction (QPD, a Chinese medicine compound formula recommended for combating COVID-19 in China) against human drug-metabolizing enzymes and to assess the pharmacokinetic interactions in vivo. The results demonstrated that QPD dose-dependently inhibited CYPs1A, 2A6, 2C8, 2C9, 2C19, 2D6 and 2E1 but inhibited CYP3A in a time- and NADPH-dependent manner. In vivo test showed that QPD prolonged the half-life of lopinavir (a CYP3A substrate-drug) by 1.40-fold and increased the AUC of lopinavir by 2.04-fold, when QPD (6 g/kg) was co-administrated with lopinavir (160 mg/kg) to rats. Further investigation revealed that Fructus Aurantii Immaturus (Zhishi) in QPD caused significant loss of CYP3A activity in NADPH-generating system. Collectively, our findings revealed that QPD potently inactivated CYP3A and significantly modulated the pharmacokinetics of CYP3A substrate-drugs, which would be very helpful for the patients and clinicians to avoid potential drug-interaction risks in COVID-19 treatment.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies